Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies: The European market is capturing 30% of the global medical device field driven by rapid advances in innovative software, AI, and ML. But as medical […]

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines. Whether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks […]

RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms, as well as pharma giants partnering with innovative biotech companies to […]

The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving toxicity, PKPD, and late-stage development. Don’t miss out on the unparallel learning and networking opportunities on offer at this summit and join 90+ pioneering Directors, […]

Fresh from the reapproval of Roche/Genentech’s Susvimo, positive readouts for sustained release implants, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss […]

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it […]